重组链激酶治疗急性心肌梗塞的疗效与安全性

目的观察国产重组链激酶在急性心肌梗塞治疗中的溶栓效果和不良反应。方法自１９９７年３月～１９９８年３月间对４７７例急性心肌梗塞患者予１５０万单位重组链激酶溶栓治疗，观察溶栓再通率、急性期死亡率、并发症以及不良反应发生率。结果溶栓再通率为８０２％，３５天死亡率５０％。不良反应中：过敏反应５５％（２６例），低血压７８％（３７例），出血１５１％（７２例），１例发生颅内出血但未致残，肝功能损害１４％（７例），半月后均恢复。结论国产重组链激酶为治疗急性心肌梗塞有效、安全的溶栓药物。

Intravenous recombinant streptokinase on acute myocardial infarction

Objective To observe the clinical efficacy and safety of intravenous thrombolytic therapy using domestic recombinant streptokinase (rSK) in acute myocardial infarction (AMI) Methods Four hundred and seventy seven patients, admitted to the multicenter clinical trial group during March 1997 to March 1998, were treated by intravenous rSK (15MU) The patency of infarctrelated coronary artery was assessed by unified clinical criteria Adverse reactions were also observed Results The patency was 802%, 35day mortality was 5% The rate of allergic reaction was 55% The rate of hypotension was 78%, of bleeding was 151% (including 1 case of nonfatal intracranial hemorrhage) The rate of liver function damage was 15%, and all recovered in half a month Conclusion Domestic recombinant streptokinase is an effective, reliable and safe thrombolytic agent